Leukemia, Long-term Effects Secondary to Cancer Therapy in Adults, Long-term Effects Secondary to Cancer Therapy in Children, Lymphoma, Sexual Dysfunction and Infertility, Sexuality and Reproductive Issues, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Conditions
Keywords
long-term effects secondary to cancer therapy in adults, long-term effects secondary to cancer therapy in children, sexual dysfunction and infertility, sexuality and reproductive issues, adult acute lymphoblastic leukemia in remission, childhood acute lymphoblastic leukemia in remission, recurrent adult acute lymphoblastic leukemia, recurrent childhood acute lymphoblastic leukemia, untreated adult acute lymphoblastic leukemia, untreated childhood acute lymphoblastic leukemia, adult acute myeloid leukemia in remission, recurrent adult acute myeloid leukemia, recurrent childhood acute myeloid leukemia, untreated adult acute myeloid leukemia, untreated childhood acute myeloid leukemia and other myeloid malignancies, secondary acute myeloid leukemia, stage I adult Hodgkin lymphoma, stage I childhood Hodgkin lymphoma, stage II adult Hodgkin lymphoma, stage II childhood Hodgkin lymphoma, stage III adult Hodgkin lymphoma, stage III childhood Hodgkin lymphoma, stage IV adult Hodgkin lymphoma, stage IV childhood Hodgkin lymphoma, recurrent adult Hodgkin lymphoma, recurrent/refractory childhood Hodgkin lymphoma, unspecified adult solid tumor, protocol specific, unspecified childhood solid tumor, protocol specific, childhood acute myeloid leukemia in remission, adult acute myeloid leukemia with 11q23 (MLL) abnormalities, adult acute myeloid leukemia with inv(16)(p13;q22), adult acute myeloid leukemia with t(16;16)(p13;q22), adult acute myeloid leukemia with t(15;17)(q22;q12), adult acute myeloid leukemia with t(8;21)(q22;q22)
Brief summary
RATIONALE: Comparing results of diagnostic procedures, such as ultrasound, done before, during, and after chemotherapy may help doctors learn about the side effects of chemotherapy and help plan the best treatment. PURPOSE: This clinical trial is studying ovarian damage in young premenopausal women undergoing chemotherapy for cancer.
Detailed description
OBJECTIVES: * Determine the incidence and timing of ovarian dysfunction/damage in younger premenopausal women undergoing cytotoxic chemotherapy for cancer. * Determine the feasibility of a prospective, randomized study to assess if gonadotropin analogues can protect the ovary from the cytotoxic effects of chemotherapy. * Determine the number of patients required for adequate power to test the hypothesis. OUTLINE: This is a pilot, prospective study. Patients undergo a transvaginal or transabdominal ultrasound to measure the ovarian volume and count the number of antral follicles at baseline, 3 months after beginning cytotoxic chemotherapy, and at 6 months after completion of treatment. Patients undergo blood collection at the same time points for follicle-stimulating hormone, estradiol, and inhibin B levels. Patients are also asked to fill out questionnaires on estrogen-depletion symptoms at those times. Patients also keep a calendar of menstrual bleeding and hormonal medications. PROJECTED ACCRUAL: A total of 22 patients will be accrued for this study.
Interventions
OTHERlaboratory biomarker analysis
Patients undergo blood collection at the same time points for follicle-stimulating hormone, estradiol, and inhibin B levels.
PROCEDUREfertility assessment and management
Patients undergo a transvaginal or transabdominal ultrasound to measure the ovarian volume and count the number of antral follicles.
PROCEDUREmanagement of therapy complications
Patients are also asked to fill out questionnaires on estrogen-depletion symptoms at those times. Patients also keep a calendar of menstrual bleeding and hormonal medications.
PROCEDUREultrasound imaging
Patients undergo a transvaginal or transabdominal ultrasound to measure the ovarian volume and count the number of antral follicles.
Sponsors
National Cancer Institute (NCI)
Case Comprehensive Cancer Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
14 Years to 35 Years
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Diagnosis of cancer, including, but not limited to, any of the following: * Acute lymphocytic leukemia * Acute myeloid leukemia * Hodgkin's lymphoma * Must have primary disease with significant chance for long-term survival after therapy * Scheduled to receive chemotherapeutic agents known to be associated with ovarian failure, including any of the following: * Cyclophosphamide * Mechlorethamine hydrochloride * Busulfan * Procarbazine hydrochloride * Chlorambucil * Melphalan * Ifosfamide * Cisplatin * Carboplatin * Postmenarchal and premenopausal PATIENT CHARACTERISTICS: * Female * Weight ≤ 250 pounds * Not pregnant PRIOR CONCURRENT THERAPY: * No prior or concurrent total-body irradiation or radiotherapy to the pelvis * Concurrent bone marrow transplantation allowed * Concurrent oral contraception and/or gonadotropin releasing-hormone analogue allowed
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of ovarian damage after cytotoxic chemotherapy as determined by changes in ovarian volume, antral follicle count, and follicle-stimulating hormone, estradiol, and inhibin B levels | Ultrasound to measure the ovarian volume and count the number of antral follicles at baseline, 3 months after beginning cytotoxic chemotherapy, and at 6 months after completion of treatment. Patients undergo blood collection at the same time points. |
Countries
United States
Outcome results
None listed